Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ)
CNY 5.25
(-2.42%)
CNY 5.25
(-2.42%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 273.99 Million CNY | -24.99% |
| 2022 | 365.26 Million CNY | 87.64% |
| 2021 | 194.66 Million CNY | -83.19% |
| 2020 | 1.15 Billion CNY | -7.12% |
| 2019 | 1.24 Billion CNY | 41.46% |
| 2018 | 881.48 Million CNY | 58.6% |
| 2017 | 555.8 Million CNY | 4.68% |
| 2016 | 530.94 Million CNY | -46.83% |
| 2015 | 998.49 Million CNY | 30.01% |
| 2014 | 768 Million CNY | 36.36% |
| 2013 | 563.2 Million CNY | 60.32% |
| 2012 | 351.3 Million CNY | 23.43% |
| 2011 | 284.61 Million CNY | 124.99% |
| 2010 | 126.5 Million CNY | 132.54% |
| 2009 | 54.4 Million CNY | 15.01% |
| 2008 | 47.3 Million CNY | 42.9% |
| 2007 | 33.1 Million CNY | 10.33% |
| 2006 | 30 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 290.23 Million CNY | 5.93% |
| 2024 Q2 | 262.31 Million CNY | -9.62% |
| 2024 Q3 | 293.13 Million CNY | 13.5% |
| 2023 Q1 | 369.85 Million CNY | 1.26% |
| 2023 FY | 273.99 Million CNY | -24.99% |
| 2023 Q4 | 273.99 Million CNY | -6.74% |
| 2023 Q3 | 293.79 Million CNY | 8.98% |
| 2023 Q2 | 269.59 Million CNY | -27.11% |
| 2022 FY | 365.26 Million CNY | 87.64% |
| 2022 Q1 | 348.37 Million CNY | 78.96% |
| 2022 Q4 | 365.26 Million CNY | -5.09% |
| 2022 Q2 | 386.15 Million CNY | 10.85% |
| 2022 Q3 | 384.86 Million CNY | -0.33% |
| 2021 Q3 | 230.63 Million CNY | -29.09% |
| 2021 Q4 | 194.66 Million CNY | -15.6% |
| 2021 Q2 | 325.25 Million CNY | -58.23% |
| 2021 FY | 194.66 Million CNY | -83.19% |
| 2021 Q1 | 778.61 Million CNY | -32.77% |
| 2020 Q1 | 1.23 Billion CNY | -0.97% |
| 2020 FY | 1.15 Billion CNY | -7.12% |
| 2020 Q2 | 1.27 Billion CNY | 3.07% |
| 2020 Q3 | 1.29 Billion CNY | 1.76% |
| 2020 Q4 | 1.15 Billion CNY | -10.58% |
| 2019 Q1 | 1.02 Billion CNY | 16.44% |
| 2019 FY | 1.24 Billion CNY | 41.46% |
| 2019 Q2 | 1.18 Billion CNY | 15.6% |
| 2019 Q4 | 1.24 Billion CNY | 4.1% |
| 2019 Q3 | 1.19 Billion CNY | 0.96% |
| 2018 Q4 | 881.48 Million CNY | -8.7% |
| 2018 FY | 881.48 Million CNY | 58.6% |
| 2018 Q3 | 965.47 Million CNY | 12.22% |
| 2018 Q2 | 860.32 Million CNY | -1.86% |
| 2018 Q1 | 876.66 Million CNY | 57.73% |
| 2017 Q2 | 628.54 Million CNY | 0.24% |
| 2017 Q1 | 627.02 Million CNY | 18.1% |
| 2017 Q3 | 619.22 Million CNY | -1.48% |
| 2017 Q4 | 555.8 Million CNY | -10.24% |
| 2017 FY | 555.8 Million CNY | 4.68% |
| 2016 Q4 | 530.94 Million CNY | -11.47% |
| 2016 Q3 | 599.76 Million CNY | 6.35% |
| 2016 Q2 | 563.93 Million CNY | 13.2% |
| 2016 Q1 | 498.17 Million CNY | -50.11% |
| 2016 FY | 530.94 Million CNY | -46.83% |
| 2015 Q2 | 995.88 Million CNY | 8.95% |
| 2015 Q4 | 998.49 Million CNY | 5.87% |
| 2015 FY | 998.49 Million CNY | 30.01% |
| 2015 Q3 | 943.12 Million CNY | -5.3% |
| 2015 Q1 | 914.12 Million CNY | 19.02% |
| 2014 Q2 | 693.25 Million CNY | 12.01% |
| 2014 FY | 768 Million CNY | 36.36% |
| 2014 Q1 | 618.93 Million CNY | 9.9% |
| 2014 Q3 | 687.41 Million CNY | -0.84% |
| 2014 Q4 | 768 Million CNY | 11.72% |
| 2013 Q1 | 448.3 Million CNY | 27.61% |
| 2013 Q2 | 560.3 Million CNY | 24.98% |
| 2013 FY | 563.2 Million CNY | 60.32% |
| 2013 Q3 | 536 Million CNY | -4.34% |
| 2013 Q4 | 563.2 Million CNY | 5.08% |
| 2012 Q3 | 399.52 Million CNY | 6.0% |
| 2012 Q4 | 351.3 Million CNY | -12.07% |
| 2012 Q2 | 376.9 Million CNY | 17.78% |
| 2012 FY | 351.3 Million CNY | 23.43% |
| 2012 Q1 | 320 Million CNY | 12.43% |
| 2011 Q2 | 229.53 Million CNY | 22.07% |
| 2011 FY | 284.61 Million CNY | 124.99% |
| 2011 Q4 | 284.61 Million CNY | 1.47% |
| 2011 Q3 | 280.5 Million CNY | 22.21% |
| 2011 Q1 | 188.03 Million CNY | 48.64% |
| 2010 Q1 | 52.47 Million CNY | -3.55% |
| 2010 Q4 | 126.5 Million CNY | 65.36% |
| 2010 FY | 126.5 Million CNY | 132.54% |
| 2010 Q3 | 76.5 Million CNY | -5.68% |
| 2010 Q2 | 81.11 Million CNY | 54.58% |
| 2009 Q2 | 57.17 Million CNY | 0.0% |
| 2009 FY | 54.4 Million CNY | 15.01% |
| 2009 Q4 | 54.4 Million CNY | -27.46% |
| 2009 Q3 | 74.99 Million CNY | 31.17% |
| 2008 Q4 | 47.3 Million CNY | 0.0% |
| 2008 FY | 47.3 Million CNY | 42.9% |
| 2007 FY | 33.1 Million CNY | 10.33% |
| 2006 FY | 30 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 2.54 Billion CNY | 89.225% |
| Zhejiang Zhenyuan Share Co., Ltd. | 138.12 Million CNY | -98.363% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | 593.88 Million CNY | 53.863% |
| Hubei Guangji Pharmaceutical Co., Ltd. | 935.85 Million CNY | 70.722% |
| Yifan Pharmaceutical Co., Ltd. | 1.99 Billion CNY | 86.267% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | 4.36 Million CNY | -6176.153% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 7.55 Billion CNY | 96.374% |
| Boai NKY Medical Holdings Ltd. | 60.4 Million CNY | -353.579% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 62.44 Million CNY | -338.798% |